What's My Infusion Center Worth?
We value your center the way a private-equity or strategic buyer will, from adjusted earnings up through payer and drug mix, so you know your range before anyone else does.
Run the estimator →
Home / Who We Serve / Ambulatory Infusion
Tier-1 Specialty · Sell-Side M&A
Your Infusion Center Is Priced on Payer Mix and Drug Economics. We Value It on Both.
An ambulatory infusion center is not valued like a cash-pay aesthetics practice; it is valued on the reimbursement it can repeat, the therapies it administers, and how durable that revenue is once a buyer underwrites it. We help owners see that number clearly before any buyer does, then build toward it.
What's your infusion center actually worth?
A confidential ballpark in under two minutes, no email required.
Why Infusion Centers Are Different
Why an Ambulatory Infusion practice is valued differently.
Unlike a cash-pay aesthetics practice, an ambulatory infusion center earns most of its revenue through reimbursement, and a large share of the drugs it administers fall under Medicare Part B J-codes priced at ASP plus six percent. That structure compresses margins and means a buyer looks first at your payer mix, your drug mix, and the durability of your contracts, not at a single good billing month. The therapies you administer, from biologics for autoimmune conditions to oncology and specialty infusions, set the economic floor and ceiling of what your practice is worth.
The sector is growing for real reasons: rising demand for outpatient care, expanding biologic therapies for chronic conditions, and a healthcare system that needs cost-effective delivery models for specialty medication administration. A buyer underwrites future cash flow, so they pay for what reliably repeats. We position infusion service providers to capitalize on those trends by showing exactly how reimbursement optimization, operational efficiency, and clean compliance translate into a higher, more defensible multiple.
Payer Mix and Reimbursement Quality
Buyers underwrite your payer mix and contracts before anything else. Strong commercial-payer concentration and well-managed revenue cycle signal stability; a Medicaid-heavy mix or thin J-code spreads pull the multiple toward the bottom of the range.
Drug Mix Drives the Value
The therapies you administer set your economics. A book weighted toward biologics for autoimmune, oncology, or specialty conditions earns a different multiple than a commoditized one, because the drug mix is what a buyer is really acquiring.
Operational Efficiency and Throughput
Staffing models, patient throughput, and chair utilization show how much capacity is actually transferable. A center that runs efficiently on a documented model carries more value than one that depends on the owner being in the building.
Compliance as a Selling Point
In a reimbursement-exposed business, a clean regulatory and billing-compliance framework becomes a selling point rather than a buyer concern. Documented compliance reduces a buyer's perceived risk and protects your position through diligence.
| Medicaid-heavy / commoditized drug mix | Lowest in range | Selective |
| Balanced commercial mix / specialty therapies | Mid-range | Strong |
| Strong commercial concentration / biologic & specialty-led | Top of range | Competitive |
Because no published infusion-specific multiple exists, we apply a clearly labeled general medical-practice proxy of roughly 5x to 10x adjusted EBITDA (directional only), with single-site practices toward the lower turns and multi-state specialty or home-infusion platforms toward the top. This band sits lower and runs reimbursement-exposed because Medicare Part B J-codes are priced at ASP plus six percent, which compresses margin; this is not a cash-pay thesis. Drug mix and payer mix move you within the range.
How Value Is Built
We publish the math, then tighten it for you.
The pattern is public. Payer mix, drug mix, and scale move an infusion center from an owner-run clinic to an investable platform. Your confidential report normalizes your earnings, applies your real comps, and shows which moves widen the spread in your favor.
Run my numbers →See Your Number First
Know your number before anyone else does.
A confidential ballpark in under two minutes. No email required to see your range. The estimate is generated on your device. Nothing is stored or sent unless you choose to continue.
Step 1 · Instant ballpark
$3.0M
Estimated enterprise value
$1.4M – $4.7M
Practices like yours trade around 2.6x – 5.3x adjusted earnings.
What raises your number
- Build recurring revenue past 30% of sales
- Reduce owner-performed treatment dependence
- Clean, normalized three-year financials
What lowers your number
- Owner performs the majority of clinical work
- Recurring revenue under 15% of sales
Step 2 · What you receive when you continue
Your custom valuation report. Comparable transactions, your likely buyer pool, and timing analysis.
Your buyer-readiness scorecard. The specific moves that raise your multiple before you go to market.
A confidential 30-minute strategy call with Bill Walker. No obligation, no pressure.
Your information is never shared, and we have never broken a client's confidentiality.
Estimate only. A ballpark from limited inputs plus published industry M&A benchmarks.
Infusion Center Sellers Ask
Everything that moves your number, in plain English.
Reading Your J-Code and Reimbursement Exposure
We translate how Medicare Part B ASP-plus-six economics and your payer contracts shape your multiple, so reimbursement stops being a black box.
See how J-codes affect value →Who Buys Infusion Centers
Strategic acquirers, private equity platforms, and roll-ups each underwrite differently; we help you read which buyer type fits your therapies and your goals.
Match buyer to your book →When Is the Right Time to Sell?
The right window depends on your growth rate, contract stability, and drug mix; we help you read whether your center is positioned now or needs a season of prep first.
Read your readiness →De-Risking Owner and Key-Person Dependence
If the center runs on you, a buyer discounts it; we help shift clinical delivery, protocols, and payer relationships onto a transferable team.
Test the impact →Confidentiality and Protecting Your Staff
We run every process under strict confidentiality with NDAs, staged disclosure, and anonymized data, so your team, referral sources, and competitors learn nothing until you decide they should.
Our confidentiality method →Infusion Center Track Record · Anonymized
Discretion is the proof.
Single-site Infusion Center
$00.0M
Sell-side advisor
Specialty Infusion Center
$00.0M
Sell-side advisor
Multi-state Infusion Platform
$00.0M
Sell-side advisor
Home-Infusion Provider
$00.0M
Sell-side advisor
Tombstone values redacted by design. The published board uses Aesthetic Brokers' verified, client-consented anonymized deals only.
What Makes This Vertical Unique
What Makes Selling an Infusion Center (AIC) Different
An ambulatory infusion center is not a med spa, not a surgical practice, and not a cash-pay clinic. Its economics run on reimbursement, its value is anchored in drug mix and payer contracts, and its buyer pool is shaped by platform-building logic that most generalist brokers have never worked through. Understanding these differences before you go to market is how you protect your number.
Commercial Payer Concentration
A buyer's first read of your financials is the payer breakdown. A center with strong commercial-payer concentration carries more durable margin than a Medicaid-heavy book, because commercial rates compress less under Medicare Part B ASP-plus-six pricing. Payer mix is not a footnote; it sets the ceiling of what a buyer will offer.
Drug Mix and Therapy Profile
The therapies you administer determine your economics more than your revenue line does. A center with a biologic-heavy or specialty-infusion book in autoimmune, oncology, or rare-disease categories reads as a different asset than a commoditized general-infusion operation. Buyers are acquiring a drug mix as much as a business.
A Transferable Operating Model
Chair utilization, staffing ratios, patient throughput, and documented clinical protocols all show how much of the center's output is tied to systems versus tied to the owner. A center that functions as a repeatable model is an investable platform. A center that runs because the owner is present every day is priced accordingly.
Referral Source Depth and Durability
Infusion centers grow through relationships with oncologists, rheumatologists, neurologists, and other referring physicians. Buyers examine whether those relationships belong to the practice or to the individual owner. A well-documented, diversified referral network that survives a transition adds material value; one built entirely on a single physician's relationships is a diligence risk.
Medicaid Concentration and Thin J-Code Margins
When a significant share of volume comes through Medicaid or is tied to J-codes priced at ASP plus six percent with no meaningful margin above cost, a buyer's EBITDA normalization produces a lower earnings base. Low-margin reimbursement volume is not discounted dollar for dollar; it is discounted in both the earnings and the multiple, a compounding effect most sellers do not see coming.
Single-Owner Clinical and Payer Dependency
If the center's payer contracts were negotiated by you, its referral sources call your cell phone, and clinical oversight runs through you personally, a buyer will model what happens when you are gone. The answer produces a discount. Separating these relationships from the owner before going to market is one of the highest-return things a seller can do.
Compliance Gaps and Billing Irregularities
In a reimbursement-exposed business, diligence on billing practices and compliance documentation is thorough by design. Buyers and their advisors will audit coding accuracy, prior authorization processes, and any history of overpayment demands or payer audits. Gaps that can be explained pre-diligence become negotiating points post-diligence, and post-diligence leverage almost always moves in the buyer's direction.
What a Specialist Sees That a Generalist Misses
A generalist business broker evaluates an infusion center the same way they evaluate a landscaping company: revenue, profit, and years in business. That approach misses everything that actually moves an AIC's value.
We read the payer mix by contract tier, not by aggregate revenue. We read the drug formulary by margin profile, not by billing volume. We know which buyers are building specialty-infusion platforms, which are building geographic density, and which are underwriting for add-on thesis fit. We position the center for the buyer whose thesis it fits best, not the first buyer who submits a letter of intent.
That positioning difference, applied before a buyer has seen your numbers, is where your outcome is shaped. A generalist advisor running a process built for med spas or dental practices will not know to build that case. We do it for every AIC seller we represent.
Infusion Center Sale FAQ
Straight answers, before you commit to anything.
An ambulatory infusion practice is valued on its adjusted EBITDA with a multiple applied on top. Because no published infusion-specific multiple exists, we apply a clearly labeled general medical-practice proxy of roughly 5x to 10x, directional only. Because most revenue is reimbursement-based and many drugs fall under Medicare Part B J-codes priced at ASP plus six percent, a buyer weighs your payer mix, drug mix, and contract stability far more heavily than a single month of billing.
An infusion center earns most of its revenue through reimbursement, not cash at the point of care, so its value is reimbursement-exposed rather than cash-pay. Medicare Part B J-codes priced at ASP plus six percent compress margins, which is why the multiple range starts lower and why your drug mix and payer concentration drive what a buyer will pay.
J-codes are the billing codes for drugs administered by infusion, and many are reimbursed under Medicare Part B at the drug’s average sales price plus six percent. That formula limits the margin on those therapies, so buyers look closely at your drug mix and payer concentration. A book weighted toward stronger-margin specialty or commercial therapies supports a higher multiple within the range.
Infusion centers offer recurring revenue streams, scalable operations, lower overhead than hospitals, growing patient demand, and the ability to deliver cost-effective care for chronic conditions that require regular therapy. Buyers value the predictability of that demand and the room to add chairs, sites, or therapies, which is why a well-run center can command competitive interest.
The transaction process typically takes six to twelve months from initial valuation to closing, depending on practice complexity and buyer requirements. The entire process can stay confidential. We use confidentiality agreements, secure data rooms, and a vetted buyer process so your staff, patients, referral sources, and competitors learn nothing until you decide they should.
Key value drivers include optimizing operational efficiency and chair throughput, strengthening payer contracts and commercial concentration, improving your drug-mix quality, expanding service offerings, deepening referral relationships, maintaining excellent compliance records, and demonstrating durable growth. The goal is value that survives your reduced hours, because a center that depends on the owner is discounted by buyers.
Who you work with
You are advised by Bill Walker, not handed to a junior associate.
Bill Walker founded Aesthetic Brokers after leading mergers and acquisitions for a large private-equity-backed healthcare services organization. Before that he flew for the Marine Corps at the Presidential Helicopter Squadron and commanded a squadron in combat. He knows how an investor values a practice, and how to make sure that value lands with you, not the buyer.
Talk with Bill about your practiceYour infusion center deserves an uncommon partner.
Start with a confidential, two-minute read on where you stand.